Catalog No.
DHD14804
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1
Clonality
Monoclonal
Applications
Research Grade Biosimilar
Target
Hyaluronate receptor, MDU2, HUTCH-I, MDU3, Phagocytic glycoprotein I, CDw44, Epican, Phagocytic glycoprotein 1, ECMR-III, CD44, Hermes antigen, PGP-1, PGP-I, GP90 lymphocyte homing/adhesion receptor, LHR, CD44 antigen, MIC4, Extracellular matrix receptor III, Heparan sulfate proteoglycan
Concentration
4.35 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P16070
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
RG7356
Clone ID
RG7356
Note
For research use only. Not suitable for clinical or therapeutic use.
Global quantitative phosphoproteome analysis of human tumor xenografts treated with a CD44 antagonist., PMID:22777824
Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44., PMID:23530247
Preclinical evaluation of 89Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cynomolgus monkeys: Prelude to Phase 1 clinical studies., PMID:24492295
Anti-CD44 mAb for the treatment of B-cell chronic lymphocytic leukemia and other hematological malignancies: evaluation of WO2013063498., PMID:24798704
CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients., PMID:25762343
Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia., PMID:27081038
Targeting Tumor Cells with Anti-CD44 Antibody Triggers Macrophage-Mediated Immune Modulatory Effects in a Cancer Xenograft Model., PMID:27463372
First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors., PMID:27507056
Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody., PMID:29356983
For research use only. Not for human or drug use.
